Novel Coronavirus Pneumonia (COVID-19)
Conditions
Interventions
Third dose of SARS-CoV-2 vaccine group:administering third dose of SARS-CoV-2 vaccine
Sponsors
The Afiliated Hospital of Yunnan University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. The participants were 18 to 75 years old, male or female; 2. Two doses of inactivated SARS-CoV-2 vaccine were administered recently and the interval between two doses was 3-5 weeks; 3. The neutralization antibody levels were negative or less than 20% average antibody level of COVID-19 recovered patients in 14 days after administering two doses of SARS-CoV-2 vaccine; 4. It is now in 4-24 weeks after administering second dose of SARS-CoV-2 vaccine; 5. Participants can follow the researchers guidance to accomplish the research process.
Exclusion criteria
Exclusion criteria: 1. The history of SARS-CoV-2 infection; 2. The History of vaccination against other types of SARS-CoV-2 vaccine other than inactivated SARS-CoV-2 vaccine; 3. Severe mental and neurological disease; 4. The following common disease (coronary heart disease, hypertension, diabetes, chronic respiratory diseases, tumors, etc.) and poorly controlled; 5. Immune deficiency or immunosuppressive therapy patients; 6. According to the researchers, any other factors that the subjects do not fit to participate in this clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Neutralizing antibody level;Antigen-specific memory T cells; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of adverse events;Incidence of serious adverse events; | — |
Countries
China
Contacts
Public ContactWei Jia
The Affiliated Hospital of Yunnan University
Outcome results
None listed